Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17819877 | 0.92 | SPHK1 (0.49) | SPHK1BRD4HSD11B2HCRTR2CHRM2 | |
| SCHEMBL16545981 | 0.92 | SPHK1 (0.49) | SPHK1BRD4HSD11B2HCRTR2CHRM2 | |
| SCHEMBL10211186 | 0.92 | SPHK1 (0.49) | SPHK1BRD4HSD11B2HCRTR2CHRM2 | |
| SCHEMBL10211309 | 0.86 | SPHK1 (0.51) | SPHK1BRD4HSD11B2HCRTR2CHRM2 | |
| SCHEMBL30695343 | 0.86 | SPHK1 (0.46) | SPHK1BRD4HSD11B2HCRTR2CHRM2 | |
| SCHEMBL17244141 | 0.86 | SPHK1 (0.48) | SPHK1BRD4HSD11B2HCRTR2CHRM2 | |
| SCHEMBL31362554 | 0.85 | SPHK1 (0.47) | SPHK1BRD4HSD11B2HCRTR2CHRM2 | |
| SCHEMBL18595256 | 0.85 | SPHK1 (0.47) | SPHK1BRD4HSD11B2HCRTR2CHRM2 | |
| SCHEMBL15318844 | 0.84 | SPHK1 (0.48) | SPHK1BRD4HSD11B2HCRTR2CHRM2 | |
| SCHEMBL1068504 | 0.84 | SPHK1 (0.48) | SPHK1BRD4HSD11B2HCRTR2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001889-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4522622-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220439-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001889-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SF3B1, SF3A1, SF3B5 | SPHK1 4261/4885BRD4 3492/4885HSD11B2 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.